GleamWall
中文EN

VCYT VERACYTE, INC.

Services-Medical Laboratories · Nasdaq · SEC CIK 1384101 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY17.5%
TTM net income YoY318.4%
TTM EPS YoY305.3%
Revenue 3-yr CAGR19.2%
Net income 3-yr CAGR—

Margins

Gross margin72.0%
Operating margin17.1%
Net margin21.8%
FCF margin27.8%
EBITDA margin20.8%

Returns

ROE9.4%
ROA8.6%
ROIC (approx.)9.1%
Asset turnover0.40x

Leverage & solvency

Liabilities / assets8.9%
Debt / equity0.00x
Current ratio5.56x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.37x
Accruals ratio-3.2%
Payout ratio—
Capex / revenue2.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$151.75M$150.32M$139.07M$140.64M$131.87M$130.16M$114.47M$118.63M
Gross profit$107.10M$108.55M$101.16M$101.97M$91.28M$89.77M$79.51M$78.75M
R&D expense$32.16M$29.44M$27.10M$20.85M$15.98M$16.26M$17.72M$19.29M
SG&A expense$29.30M$27.44M$23.68M$17.37M$27.28M$32.33M$33.81M$26.91M
Operating income$16.57M$22.98M$22.65M$37.20M$22.95M-$5.27M$2.90M$4.17M
Pretax income$21.12M$26.52M$29.97M$40.63M$18.89M$1.25M$7.43M$3.44M
Income tax-$10.38M$1.03M$1.27M-$515,000-$248,000$2.23M$381,000-$1.67M
Net income$31.50M$25.49M$28.71M$41.15M$19.14M-$980,000$7.05M$5.11M
EBITDA$22.55M$27.82M$28.08M$42.49M$28.21M$221,000$8.27M$10.43M
EPS (basic)0.390.320.36—0.24-0.010.09—
EPS (diluted)0.380.310.35—0.24-0.010.09—
Weighted avg. shares (diluted)82.78M82.06M81.31M—79.69M78.39M80.06M—
Balance sheet
Cash & equivalents$199.83M$299.52M$263.14M$362.58M$317.21M$221.15M$187.76M$240.63M
Short-term investments———$50.31M————
Receivables$56.79M$54.18M$50.11M$44.66M$47.83M$50.81M$53.78M$46.52M
Inventory———$20.55M$20.33M$25.02M$24.25M$21.75M
Current assets$467.88M$574.77M$522.17M$488.38M$449.22M$414.68M$383.15M$372.27M
PP&E, net$24.87M$21.93M$22.65M$22.19M$18.90M$18.55M$22.53M$22.95M
Goodwill$855.58M$767.15M$767.15M$767.15M$767.15M$773.25M$754.27M$745.80M
Intangibles$184.88M$82.70M$85.86M$89.15M$92.48M$95.81M$99.09M$102.30M
Total assets$1.57B$1.49B$1.44B$1.41B$1.37B$1.34B$1.32B$1.30B
Current liabilities$84.21M$62.74M$56.12M$59.94M$72.15M$76.43M$75.12M$78.63M
Total liabilities$139.99M$97.96M$91.99M$96.44M$110.12M$123.05M$120.47M$124.07M
Shareholders' equity$1.43B$1.39B$1.34B$1.31B$1.26B$1.22B$1.19B$1.18B
Shares outstanding80.66M80.36M79.79M79.36M79.03M78.60M78.31M77.77M
Cash flow statement
Operating cash flow$40.26M$45.83M$35.22M$52.58M$44.76M$33.60M$5.36M$24.52M
Capital expenditure$2.33M$2.86M$2.96M$3.78M$2.79M$1.29M$1.82M$4.14M
Free cash flow$37.92M$42.97M$32.25M$48.80M$41.97M$32.32M$3.54M$20.38M
Investing cash flow-$139.47M-$13.54M-$127.96M-$5.43M$48.26M-$224,000-$51.82M-$54.14M
Financing cash flow-$479,000$4.14M-$6.63M-$149,000$2.98M-$566,000-$6.48M-$4.51M
Depreciation & amortization$5.98M$4.84M$5.43M$5.30M$5.27M$5.49M$5.36M$6.25M
Stock-based compensation$13.96M$14.09M$12.76M$10.90M$10.76M$10.98M$10.96M$9.63M

Free plan shows the latest 8 periods; Pro shows all 59 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.